Details for New Drug Application (NDA): 065332
✉ Email this page to a colleague
NDA 065332 describes CEFDINIR, which is a drug marketed by Alkem Labs Ltd, Anda Repository, Aurobindo Pharma, Lupin, Sandoz, and Teva Pharms, and is included in twelve NDAs. It is available from twenty-eight suppliers. Additional details are available on the CEFDINIR profile page.
The generic ingredient in CEFDINIR is cefdinir. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the cefdinir profile page.
The generic ingredient in CEFDINIR is cefdinir. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the cefdinir profile page.
Summary for 065332
| Tradename: | CEFDINIR |
| Applicant: | Teva Pharms |
| Ingredient: | cefdinir |
| Patents: | 0 |
Suppliers and Packaging for NDA: 065332
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CEFDINIR | cefdinir | FOR SUSPENSION;ORAL | 065332 | ANDA | Teva Pharmaceuticals USA, Inc. | 0093-4136 | 0093-4136-64 | 60 mL in 1 BOTTLE (0093-4136-64) |
| CEFDINIR | cefdinir | FOR SUSPENSION;ORAL | 065332 | ANDA | Teva Pharmaceuticals USA, Inc. | 0093-4136 | 0093-4136-73 | 100 mL in 1 BOTTLE (0093-4136-73) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 125MG/5ML | ||||
| Approval Date: | May 4, 2007 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | FOR SUSPENSION;ORAL | Strength | 250MG/5ML | ||||
| Approval Date: | May 4, 2007 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
